Single versus dual antiplatelet therapy for feMOrOpopliTeal lesion treated witH paclItaxEl-eluting device.

INTERVENTION: After EVT, antiplatelet therapy is followed up with DAPT for 3 months after surgery / aspirin monotherapy group for 12 months and clopidogrel monotherapy group for 12 months. CONDITION: Symptomatic arteriosclerosis obliterans PRIMARY OUTCOME: Primary patency rate of target lesions at 12 months after procedure SECONDARY OUTCOME: 1.Death, myocardial infarction, stroke; 2.MAE(death, myocardial infarction, stroke, amputation of the lower extremities, ALI, surgical bypass, ; any re‐intervention); 3.MALE(ALI, surgical bypass, any re‐intervention)avoidance rate; 4.CD‐TLR,TLR,TVR; 5.Any reintervention; 6.ALI; 7.surgical bypass; 8.Hemorrhagic event bleeding that falls under 3 or 5 of the BARC criterion; (Intracranial bleeding,Gastrointestinal bleeding); 9.Changes in resting ABI; 10.Rutherford Classification Trends INCLUSION CRITERIA: 1.Patients with symptomatic superficial femoral artery(SFA)or proximal popliteal artery(PA)target lesions requiring peripheral revascularization(whether new or restenotic) 2. Patients scheduled for endovascular treatment(EVT)using a paclitaxel‐eluting device(drug‐eluting stent (DES)or drug‐coated balloon(DCB))for the lesions of(1)above 3.Patients with a Rutherford classification of 2‐4 4.Patients who can continue DAPT for 3 months